Translational Oncology Research Program

转化肿瘤学研究计划

基本信息

批准号：
10712120
负责人：
JILL MARIE KOLESAR
金额：
$ 22.5万
依托单位：
UNIVERSITY OF KENTUCKY
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-07-08 至 2028-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10712120
关键词：
Address Antineoplastic Agents Appalachian Region Area Award Basic Science Biological Markers Biological Models Breast Cancer Burden Cancer Center Cancer Center Support Grant Cancer Control Cancer Patient Catchment Area Clinic Clinical Clinical Oncology Clinical Trials Clinical Trials Network Collaborations Colorectal Cancer Communities Community Outreach Data Development Devices Diet Direct Costs Disparity EIF4EBP1 gene Early Therapeutic-Clinical Trials Network Early identification Electronics Enrollment FASN gene Fostering Funding Future Genomics Goals Gold Compounds Hydroxychloroquine Incidence Individual Infrastructure Institution Interdisciplinary Study International Intestinal Hormones Investigational Drugs Investigational Therapies Kentucky Lead Leadership Malignant Neoplasms Manuscripts Mediator Mission Molecular Molecular Target Multi-Institutional Clinical Trial Mutation NCI Center for Cancer Research National Cancer Institute Natural Products Nursing Faculty Obesity Oncology Participant Patient-Focused Outcomes Patients Peer Review Pharmaceutical Preparations Phase Phenotype Population Prostate Public Policy Publications Publishing Radiopharmaceuticals Research Research Personnel Research Priority Resources Role Ruthenium Compounds Science Strategic Planning Structure Therapeutic Therapeutic Agents Therapeutic Intervention Translating Translations Tumor Suppressor Proteins United States National Institutes of Health Universities Up-Regulation Validation anticancer treatment cancer care cancer prevention cancer therapy cellular oncology clinical development clinical translation clinical trial enrollment clinically relevant college community engagement cross disciplinary program design drug repurposing early phase clinical trial ethnic disparity genome resource inhibitor insight inter-institutional intervention program investigator-initiated trial member molecular oncology mortality next generation sequencing novel novel anticancer drug novel therapeutic intervention novel therapeutics oncology program phase 1 study pre-clinical precision medicine preclinical development programs racial disparity recruit repository translational goal translational oncology translational pipeline translational study treatment trial tumor working group

项目摘要

PROJECT SUMMARY/ABSTRACT The Markey Cancer Center’s (MCC) Translational Oncology (TO) Research Program is scientifically focused on identifying novel targets, discovering new anticancer agents and devices, and leading catchment- relevant clinical trials to decrease cancer burden in Kentucky and the nation. The overarching theme of the TO Program is to use precision medicine to enhance patient outcomes through three Specific Aims: 1) Identify and validate mechanistic targets of cancer, 2) Discover, re-design and develop new anticancer agents and devices, and 3) Develop and lead biomarker directed, catchment-relevant clinical trials. Currently, 33 ongoing translational studies are evaluating molecular targets and mediators of cancer. Since 2018, 38 new drugs, novel combinations and repurposed anticancer agents and devices have been developed, with a focus on identified mutations and phenotypes as informed by COE catchment area data. TO is a cross-disciplinary program with 67 investigators from four colleges and 16 departments producing research awards of approximately $10M in annual direct costs, a 68% increase from 2017, including $1.8M from the NCI and $3.4M from other NIH agencies. Members have published 613 manuscripts (2018 to 2022), of which 148 (24%) are inter-programmatic, 169 (28%) are intra-programmatic, 344 (56%) are inter-institutional, and 13% of which have an impact factor >10. TO members lead 26 new therapeutic interventional investigator-initiated trials (IITs), a 53% increase since the previous funding period (17 IITs, 2013-2017). These IITs have enrolled 870 patients (2018-2022), a 111% increase in IIT accruals (413 patients, 2013-2017), with 52% of participants from Appalachia. In addition, TO investigators enrolled 12,689 individuals to the program’s interventional and non-interventional trials, compared to 8,571 from 2013-2017, a 48% increase. TO Program members are international leaders in target discovery and validation, have national and international collaborations and hold leadership roles in the National Cancer Institute’s Experimental Therapeutics Clinical Trials Network, the Oncology Research Information Exchange Network and Onco-Array Networks, and the MCC-led Global Cancer Consortium. The TO Program fosters continuous collaboration among MCC program members to inform and advance MCC basic science into the clinic. Examples include translating early identification of the biomarker FASN to an ongoing colorectal cancer trial and demonstrating the upregulation of tumor suppressor PAR-4 by hydroxychloroquine in three trials. The TO Program has a cohesive and collaborative team focused on translating MCC scientific discoveries into safe and effective anticancer treatments with a demonstrated depth and breadth of impact in MCC’s catchment area, nationally and internationally.

项目概要/摘要马基癌症中心 (MCC) 的转化肿瘤学 (TO) 研究计划是科学的专注于识别新靶点，发现新的抗癌药物和设备，并引领流域- 减少肯塔基州和全国癌症负担的相关临床试验。该计划旨在通过三个具体目标使用精准医学来提高患者的治疗效果：1) 识别和验证癌症的机制目标，2) 发现、重新设计和开发新的抗癌药物和设备， 3) 开发并领导生物标志物导向的、与流域相关的临床试验，目前正在进行 33 项临床试验。自 2018 年以来，转化研究正在评估癌症的分子靶点和介质。已经开发出新的组合和重新利用的抗癌药物和设备，重点是根据 COE 流域数据确定突变和表型是一项跨学科的工作。该计划由来自 4 个学院和 16 个部门的 67 名研究人员组成，颁发的研究奖项为年度直接成本约 1000 万美元，比 2017 年增加 68%，其中包括来自 NCI 的 180 万美元和来自 NIH 其他机构的 340 万美元资助已发表 613 篇手稿（2018 年至 2022 年），其中 148 篇。 (24%) 是计划间的，169 (28%) 是计划内的，344 (56%) 是机构间的，13% 是影响因子 >10 的 TO 成员领导了 26 名新的治疗介入研究者发起的项目。试验 (IIT)，自上一资助期以来增加了 53%（17 个 IIT，2013-2017 年）。这些 IIT 已入组。 870 名患者（2018-2022 年），个人所得税应计增加 111%（413 名患者，2013-2017 年），参与者比例为 52% 此外，TO 调查人员还招募了 12,689 名个人参加该计划的干预和治疗。与 2013 年至 2017 年的 8,571 项非干预性试验相比，TO 计划成员增加了 48%。目标发现和验证领域的国际领导者，开展国内和国际合作并举办在国家癌症研究所实验治疗临床试验网络中担任领导角色肿瘤学研究信息交换网络和 Onco-Array 网络，以及 MCC 领导的全球网络癌症联盟。TO 计划促进 MCC 计划成员之间的持续合作，以为 MCC 基础科学提供信息并将其推进临床。例子包括将早期识别转化为临床。生物标志物 FASN 用于正在进行的结直肠癌试验并证明肿瘤抑制因子的上调羟氯喹的 PAR-4 正在进行三项试验，TO 计划拥有一支团结协作的团队。将 MCC 的科学发现转化为安全有效的抗癌治疗方法 MCC 业务范围内的国内和国际影响的深度和广度。